RELB KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 65 bp deletion in exon 4.
I-Rel, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, RELB_HUMAN, Reticuloendotheliosis viral oncogene homolog B, Transcription factor Rel B, v rel avian reticuloendotheliosis viral oncogene homolog B, v rel reticuloendotheliosis viral oncogene homolog B
RELB KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 65 bp deletion in exon 4.
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Rel B also known as RELB proto-oncogene is a member of the NF-κB family of transcription factors. This protein plays a significant role in regulating gene expression. Rel B has a molecular mass of approximately 68 kDa. It expresses in diverse tissues including lymphoid organs and epithelial cells. It generally resides in the cytoplasm and translocates to the nucleus upon activation.
Rel B serves as a critical component of the alternative NF-κB signaling pathway. It often forms a complex with another NF-κB family member called p52. This complex controls the transcription of genes involved in the immune response cell survival and differentiation. Additionally Rel B contributes to the development of secondary lymphoid organs and modulation of immune responses.
Rel B integrates into the non-canonical NF-κB signaling pathway also influencing the canonical pathway to a lesser extent. In the non-canonical pathway Rel B interacts with NIK and p100 to influence immune cell function. This involvement makes Rel B essential in processes like adaptive immunity and inflammatory responses. The protein p52 closely associates with Rel B aiding its activity in these pathways.
Rel B has connections to autoimmune diseases and certain cancers. Abnormal Rel B activity can lead to chronic inflammation and contribute to conditions like rheumatoid arthritis. In cancer its deregulation associates with lymphomas where it may interact with other NF-κB proteins like p50 and RelA affecting cell proliferation and survival. Understanding Rel B in these contexts could provide insights into therapeutic targets.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Anti-Rel B antibody [EP614Y] ab33907 was shown to react with Rel B in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab265948 (knockout cell lysate Human RELB (Rel B) knockout HeLa cell lysate ab257635) was used. Wild-type HeLa and RELB knockout HeLa cell lysates were subjected to SDS-PAGE. Anti-Rel B antibody [EP614Y] ab33907 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4° at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Rel B antibody [EP614Y] (Anti-Rel B antibody [EP614Y] ab33907) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 40 µg
Lane 2: RELB knockout HeLa cell lysate at 40 µg
Lane 2: Western blot - Human RELB (Rel B) knockout HeLa cell line (ab265948)
Lane 3: Raji cell lysate at 40 µg
Lane 4: LnCap cell lysate at 40 µg
Performed under reducing conditions.
Predicted band size: 62 kDa
Observed band size: 70 kDa
Homozygous: 65 bp deletion in exon 4.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com